Welcome to our dedicated page for Metagenomi news (Ticker: MGX), a resource for investors and traders seeking the latest updates and insights on Metagenomi stock.
Metagenomi Inc (MGX) is a clinical-stage biotechnology company pioneering next-generation gene editing systems derived from metagenomic discovery. This news hub provides investors and researchers with essential updates on therapeutic developments, strategic partnerships, and scientific advancements in precision genetic medicines.
Access real-time announcements covering MGX's evolving pipeline, including progress in hemophilia A therapies and novel editing tools like ultra-small base editors. The curated collection features press releases on preclinical milestones, financial reports, and collaborations advancing in vivo delivery systems for genetic disorders.
Key updates include regulatory filings, peer-reviewed research publications, and conference presentations demonstrating the company's metagenomics-powered platform. Track developments in AI-optimized enzyme design and therapeutic programs targeting previously inaccessible genetic mutations.
Bookmark this page for verified updates on MGX's progress in developing durable, single-dose therapies. Regularly refreshed content ensures stakeholders maintain informed perspectives on this innovator's role in expanding the boundaries of genome editing.
Metagenomi (MGX) presented updated preclinical data for its hemophilia A program at the ASH 66th Annual Meeting. The company's gene editing approach demonstrated sustained Factor VIII (FVIII) activity levels through more than 16 months in nonhuman primates (NHPs). The study involved three NHPs receiving a single treatment, showing FVIII activity maintenance at 72%, 9%, and 30% at the 16.5-month timepoint.
The company's lead candidate, MGX-001, which uses a B-domain deleted bioengineered FVIII construct, achieved higher FVIII activity compared to wild type FVIII at similar integration rates. The program is on track for IND filing in 2026. The treatment showed only transient elevation of liver transaminases with no other safety concerns, positioning it as a potential one-time curative treatment for both adults and children with hemophilia A.
Metagenomi (MGX) reported Q3 2024 financial results and business updates, highlighting the nomination of MGX-001, their first development candidate for hemophilia A treatment. The company demonstrated successful proof-of-concept with durable Factor VIII activity levels over 12 months in nonhuman primates. Financial highlights include $274.6 million in cash and equivalents, with runway into 2027. R&D expenses were $26.3 million and G&A expenses were $7.6 million. The company expects one to two development candidate nominations in 2025 from their Ionis collaboration programs focusing on cardiometabolic indications.
Metagenomi (Nasdaq: MGX) announced that its abstract on Factor VIII gene insertion has been accepted for oral presentation at the American Society of Hematology (ASH) 66th Annual Meeting in December 2024. The presentation will showcase preclinical proof-of-concept data for their lead candidate MGX-001, which aims to provide a single, curative treatment for hemophilia A.
The research demonstrates durable Factor VIII expression in nonhuman primates, addressing current therapy limitations that fail to prevent breakthrough bleeding. The presentation, led by VP Preclinical Alan Brooks, PhD, is scheduled for December 9, 2024, at 5:30 PM in San Diego Convention Center.
Metagenomi presented groundbreaking results for its Adenine Base Editors (ABEs) at the European Society of Gene and Cell Therapy Annual Congress in Rome. The company's ABE platform demonstrated exceptional performance across key metrics: over 95% genome targetability, achieving 95% protein knockdown in primary T-cells through triplex editing, and highly specific on-target deamination with no detectable translocations.
The platform showed excellent tolerability with no adverse effects on cell viability or expansion. Notable advantages include compatibility with various non-viral methods of site-specific template integration, enabling an all-in-one editing solution for next-generation cell therapies. This positions Metagenomi's ABE technology as a promising tool for both in vivo genome editing programs and ex vivo cell therapy applications.
Metagenomi (Nasdaq: MGX) presented a poster at the AIChE 7th International Conference on CRISPR Technologies, highlighting their SMART adenine base editors (ABEs). These compact editors are small enough to be packaged into a single adeno-associated virus (AAV), potentially addressing a key challenge in in vivo gene editing.
The company's SMART platform demonstrates improved editing efficiency across multiple targets and cell types, enabling pursuit of neuromuscular targets. This approach could be advantageous for treating diseases like Duchenne muscular dystrophy, ALS, and Charcot-Marie-Tooth disease type 1A.
Metagenomi has optimized the SMART platform through structure-guided engineering and advanced artificial intelligence (AI) tools, showcasing the importance of leveraging multiple techniques to advance next-generation gene editing systems.
Metagenomi (Nasdaq: MGX), a precision genetic medicines company, has announced its participation in Chardan's 8th Annual Genetic Medicines Conference on September 30, 2024. The company will be involved in two key events:
1. A fireside chat from 2:30 PM to 3:00 PM ET, featuring CEO and Founder Brian Thomas, CMO Dr. Sarah Noonberg, and SVP Preclinical Alan Brooks.
2. A panel discussion titled "Genome editing for gene insertion and gene correction - where we are and what's next" from 5:00 PM to 5:30 PM ET, with CEO Brian C. Thomas participating.
A live webcast of the fireside chat will be available on the company's investor relations website, with replays of both events accessible for a time.
Metagenomi (Nasdaq: MGX) has announced promising 12-month durability data for its lead hemophilia A program, MGX-001. The preclinical study in nonhuman primates (NHPs) demonstrated durable Factor VIII (FVIII) activity levels through twelve months, with two NHPs showing normal/near-normal levels (82% and 41%) and one in the mild hemophilia range (9%). The treatment, involving a single dose of AAV followed by an LNP containing Metagenomi's novel nuclease, was generally well-tolerated.
Key findings include:
- Consistent FVIII activity levels from 3-6 months to 9-12 months
- Gene integration in liver biopsies correlating with FVIII activity
- Program on track for IND filing in 2026
Metagenomi aims to provide a one-time, curative treatment for adults and children with hemophilia A and plans to leverage this platform for other secreted protein disorders.
Metagenomi (Nasdaq: MGX) presented advancements in its AI-enabled SMART Editing Platform at the CRISPR Frontiers Conference. The company showcased AI-generated compact SMART nucleases with robust genome editing activity in mammalian cells. These tools, fitting within size-constrained delivery technologies, may enable broader disease targeting.
Key highlights include:
- AI-based gene editing variants showing high efficiency in mammalian cells
- Compact base editors less than 1,000 amino acids long
- De novo, AI-generated synthetic nucleases demonstrating robust activity
- Rational engineering achieving saturating levels of editing in human cells
Metagenomi's approach combines its metagenomics database of over 11 billion proteins with AI to create novel gene editing tools, potentially accelerating drug development and opening new therapeutic applications.
Metagenomi (Nasdaq: MGX), a precision genetic medicines company, has announced its participation in two upcoming investor conferences. The company will present at the Wells Fargo Healthcare Conference on September 4, 2024, and the H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024.
Key executives, including CEO Brian Thomas, CMO Dr. Sarah Noonberg, SVP Preclinical Alan Brooks, and CFO Pamela Wapnick, will represent Metagenomi at these events. The presentations will be available via live webcast on the company's investor relations website, with replays accessible for a time.
Metagenomi specializes in developing curative therapeutics using its proprietary, metagenomics-derived toolbox. The company's comprehensive genome editing toolkit includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, positioning Metagenomi to address a wide range of genetic mutations.
Metagenomi (Nasdaq: MGX) reported Q2 2024 financial results and business updates. Key highlights include:
1. Declared MGX-001 as lead candidate for hemophilia A treatment
2. All Wave 1 Ionis collaboration programs advancing in lead optimization
3. Achieved milestone with Affini-T related to licensed technology
4. $299.9M in cash and equivalents; runway into 2027
5. R&D expenses increased to $28.3M from $22.7M YoY
6. G&A expenses rose to $8.6M from $6.6M YoY
The company plans to present 12-month NHP durability study data for MGX-001 in September 2024, accelerated from late 2024. Metagenomi aims to file an IND for hemophilia A in 2026 and nominate 1-2 development candidates for cardiometabolic programs in 2025.
FAQ
What is the current stock price of Metagenomi (MGX)?
What is the market cap of Metagenomi (MGX)?
